Data: Aflibercept consistent in DME therapy.
| Publicado en: | Ophthalmology Times Vol. 39; no. 20; pp. 36 - 37 |
|---|---|
| Autores principales: | , |
| Formato: | pictorial tables/charts Journal Article |
| Publicado: |
MJH Life Sciences
11/1/2014
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=99465491&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 99465491 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 0193032X OTI jtl: Ophthalmology Times issn: 0193032X maglogo: N pubinfo: dt: 11/1/2014 vid: 39 iid: 20 pid: 54670 pub: MJH Life Sciences place: Cranbury, New Jersey artinfo: ui: 99465491 99465491 107838397 99465491 ppf: 36 ppct: 1 formats: fmt: @attributes: type: P tig: atl: Data: Aflibercept consistent in DME therapy. aug: au: Charters, Lynda Wykoff, Charles C. sug: subj: Recombinant Proteins Macular Degeneration Diabetes Mellitus Complications Vascular Endothelial Growth Factors Antagonists and Inhibitors pubtype: Trade Publication doctype: pictorial tables/charts Journal Article ougenre: Article ab: language: English refInfo: holdings: @attributes: islocal: N |
|---|